AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-κB axis in nasopharyngeal carcinoma

Xiangting Liu1*, Zheng Hu1,2*, Jiayao Qu1,2, Jia Li1, Ke Gong1, Li Wang1,2, Jing Jiang1, Xiangning Li1, Rongzhang He1, Lili Duan1, Weihao Luo1, Chenglai Xia3,4* and Dixian Luo5,6*

1. Translational Medicine Institute, the First People’s Hospital of Chenzhou, University of South China, Hunan 432000, P.R China.
2. The First School of Clinical Medicine, Southern Medical University, Guangdong Guangzhou 51000, China.
3. South Medical University Affiliated Maternal & child Health Hospital of Foshan, Foshan 528000, P.R. China.
4. School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 520150, P.R. China.
5. Department of Laboratory Medicine, Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital), Guangdong 518000, P.R China.
6. Center for Laboratory and Pathology, National & Local Joint Engineering Laboratory for High-through Molecular Diagnosis Technology, the First People’s Hospital of Chenzhou, Southern Medical University, Hunan 423000, P.R China.

*These authors contributed equally to this work.

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).

Received: 2020.09.06; Accepted: 2020.12.31; Published: 2021.02.03

Abstract

Nasopharyngeal carcinoma (NPC) is one kind of human head and neck cancers with high incidence in Southern China, Southeast Asia and North Africa. In spite of great innovations in radiation and chemotherapy treatments, the 5-year survival rate is not satisfactory. One of the main reasons is resistance to radiotherapy which leads to therapy failure and recurrence of NPC. The mechanism underlying remains to be fully elucidated. Aldo-keto reductase B10 (AKR1B10) plays a role in the formation and development of carcinomas. However, its role in resistance to radiotherapy of NPC is not clear. In this research, the relationships between AKR1B10 expression and the treatment effect of NPC patients, NPC cell survival, cell apoptosis, and DNA damage repair, as well as the effect and mechanism of AKR1B10 expression on NPC radioresistance were explored. A total of 58 paraffin tissues of NPC patients received radiotherapy were collected including 30 patients with radiosensitivity and 28 patients with radioresistance. The relationships between AKR1B10 expression and the treatment effect as well as clinical characteristics were analyzed by immuno-histochemical experiments, and the roles of AKR1B10 in cell survival, apoptosis and DNA damage repair were detected using the AKR1B10 overexpressed cell models. Furthermore the mechanism of AKR1B10 in NPC radioresistance was explored. Finally, the radioresistance effect of AKR1B10 expression was evaluated by the tumor xenograft model of nude mice and the method of radiotherapy. The results showed AKR1B10 expression level was correlated with radiotherapy resistance, and AKR1B10 overexpression promoted proliferation of NPC cells, reduced apoptosis and decreased cellular DNA damage after radiotherapy. The probable molecular mechanism is that AKR1B10 expression activated FFA/TLR4/NF-κB axis in NPC cells. This was validated by using the TLR4 inhibitor TAK242 to treat NPC cells with AKR1B10 expression, which reduced the phosphorylation of NF-κB.

This study suggests that AKR1B10 can induce radiotherapy resistance and promote cell survival via FFA/TLR4/NF-κB axis in NPC, which may provide a novel target to fight against radiotherapy resistance of NPC.

Key words: nasopharyngeal carcinoma; AKR1B10; radiotherapy resistance; FFA/TLR4/NF-κB axis

Introduction

Nasopharyngeal carcinoma (NPC) is a highly metastatic and aggressive malignant tumor prevalent in southern China [1]. Ionizing radiation (IR) is the primary therapeutic option for NPC. However, resistance to radiotherapy leads to therapy failure and recurrence of NPC, thus reducing the quality of life of NPC patients. It is therefore important to elucidate the mechanism underlying the radiation resistance in NPC patients.

IR directly induces DNA damage, largely by introducing single or double-stranded breaks in the DNA. Irreversible DNA damage leads to cell senescence, mitotic disorders, necrosis and/or induction of apoptosis [2]. To maintain genomic
integrity, the DNA damage response (DDR) is rapidly activated. Ataxia telangiectasia mutated (ATM) activation and phosphorylation is a main event occurring during the DDR. ATM-mediated signaling contributes to cell cycle arrest and downstream DNA repair. Subsequently, a histone variant H2AX is phosphorylated at serine 139 (γH2AX) when double-stranded breaks (DSBs) occur in cells. γH2AX is a biomarker of the cellular response to DSBs and can reflect the status of DNA damage and repair. Compared to normal cells, tumor cells are actively dividing, and DNA damage repair mechanisms are often defective and DNA damage cannot be repaired. In order to deal with DDR, the RAD9-HUS1-RAD1(9-1-1) complex is recruited to the site of DNA damage and promotes ATR-mediated phosphorylation and activation of CHK1, a human effector checkpoint protein kinase which regulates S phase progression and G2/M cell cycle arrest[3]. The MRE11-RAD50-NBS1 (MRN) complex identifies DSBs, which then recruits ATM and promotes the formation of histone-intervened H2AX (γH2AX) [4,5]. This endogenous resistance to radiotherapy leads to local recurrence and distant metastasis of cancer.

Aldo-Keto Reductase Family 1 B10, AKR1B10, is a member of the aldo-keto reductase superfamily. AKR1B10 may play a role in cancer development and progression through a variety of molecular mechanisms including the detoxification of cytotoxic carbonyls, modulation of retinoic acid levels, and regulating cellular fatty acid synthesis and lipid metabolism [6-8]. So we suggested that AKR1B10 may protect cells from DNA damage during radiotherapy and thus may play an important role in resistance to radiotherapy of NPC.

Nuclear factor-kappa B (NF-κB) signaling is involved in radiotherapy resistance of NPC, and inhibition of NF-κB enhances sensitivity to radiotherapy [9]. NF-κB is a group of nuclear protein factors that regulate the expression of a wide array of genes involved in the regulation of cellular physiological processes, immune response and tumorigenesis. Inhibitor of κB (IκB) regulates NF-κB activity [10]. When unstimulated, NF-κB is sequestered in the cytoplasm through interactions with IκBs [11], which cover the NF-κB nuclear localization and prevents nuclear translocation. When DNA damage occurs, the damage signal leads to IκB phosphorylation and subsequent ubiquitination and degradation. This exposes the nuclear localization sequence of NF-κB to induce the nuclear translocation of NF-κB, thereby initiating expression of the target genes [12].

Toll-like receptor 4 (TLR4) is a key pro-inflammatory factor. Due to the unique physiological and anatomical sites of NPC, nasopharyngeal epithelial cells are susceptible to EB virus and other pathogens, which develop into chronic inflammation ultimately aiding in cancer development [13]. NF-κB is an important transcription factor downstream of TLR4. IκB phosphorylation and the subsequent NF-κB nuclear translocation is characteristic of TLR4 activation [14]. Ma et al found that AKR1B10 can increase the synthesis of FFA by stabilizing a rate-limiting enzyme of lipid synthesis, ACCα, after association with it, which protects ACCα avoiding degradation through the ubiquitination-proteasome pathway [15]. Another report found that the TLR4/NF-κB signaling could be activated after treated with FFA in adipocytes and macrophages [16]. This study demonstrated that AKR1B10 activates FFA/TLR4/NF-κB axis to induce radiotherapy resistance of NPC in some cases.

Materials and Methods

Patients and tissues

This study was approved by the Ethics Review Committee of the First People's Hospital of Chenzhou. 58 NPC patients received radiotherapy during January 2016 to December 2018 were selected in this study. According to standardized evaluation criteria of published literature, the NPC patients were defined as two groups, the radioresistant and the radiosensitive [17-20]. The expression level of AKR1B10 was detected by immunohistochemistry (IHC) staining. The pathological diagnosis of all patients' specimens was confirmed by two experienced pathologists [21].

Cell culture and irradiations

NPC cell line CNE-2, and its derived cells, CNE-2/Vector and CNE-2/AKR1B10, were cultured in suitable conditions [22]. Cells were cultured in a multi-well plate for 6-MV X-ray treatment and the cells were harvested at corresponding time points.

For irradiation, the cells or the tumors were irradiated at defined doses using a Siemens PRIMUS X-ray irradiator (2 Gy/min, 6-MV, 15cm×10cm, SAD 100cm, d=5.5cm; Rad Source Tech, PRIMUS, Siemens, Germany). In our study, the radiation doses of 2, 4 and 6 Gy with a dose rate of 2 Gy/min were used, thus the duration of IR treatment are 1min, 2 min or 3 min respectively.

Lentiviral vector construction, virus infection and the establishment of stable cell line

The AKR1B10 CDS (coding DNA sequence) was cloned into the lentiviral expression vector pSIN-EF2-Puro (hereinafter referred to as pSIN-EF2) to construct the lentiviral vector pSIN-EF2/AKR1B10.
The method to establish stable AKR1B10-expression cell line has been described previously [23].

**AKR1B10-shRNA stable transfection using lentiviral infection**

The PLKO.1-puro vector was used to clone the sh-RNAs targeting AKR1B10. The sequences of shAKR1B10 were as followed. shRNA1: 5′-CCGGAA GTGAAAGAAGCAGTGAAAGGCTCGAGCCTTCA CTGCTTCTTTACATTTCCTTGAAGATTTCTTTTTTG-3′; shRNA2: 5′-CCGG GTGTTGCAATCCTCTCATTTGGCTCGAGCCAA ATGAGAGGATGCAACATTTTGTGTTAGAGGTACGTGCTTTTTTTTG-3′. The plasmids were transfected into HEK293T cells and the supernatant which contained the virus was collected at 48 and 72 h. The virus was then concentrated and transfected in CNE-2/AKR1B10 cells with polybrene (Sigma-Aldrich Co., USA). The transfected cells were selected by puromycin for at least 1 week.

**Quantitative real-time PCR**

Quantitative real-time PCR (qRT-PCR) was performed as previous report [24]. Briefly, total RNA was isolated using Trizol® reagent (Molecular Research Center, USA) and 2 μg RNA was subjected to reverse transcription reaction to obtain cDNAs (Reverse Transcription System, promega, USA). Specific quantitative real-time PCR experiments were performed using SYBR Green Power Master Mix following the manufacturer’s protocol (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as the internal control. The following primers were used: AKR1B10 forward (5′-CCCAGGAGACAGAGGTTATA-3′) and reverse (5′-GAAATGATTCTGAGTGAGCAGG TAG-3′); GAPDH forward (5′-ACCACAGTCCATGCATCAC-3′) and reverse (5′-TCCACCCCGTCTGCT GTA-3′).

**Clonogenic assays**

Cells were seeded in cell culture dish and irradiated with various doses of γ-radiation at room temperature. The cells were cultured in an incubator for 12 to 14 days. Cells were fixed and stained with a solution containing 0.5% crystal violet in methanol and the dishes with colonies of >50 cells were counted manually.

**Annexin V-APC/7-AAD Apoptosis Assay**

Cells were seeded in a cell culture dish, after culture cells for 24 h, exposed to radiotherapy. After 48 h, the cells were harvested and stained with the Annexin V-APC/7-AAD Apoptosis Detection Kit (BestBio, BB-41034, China). The stained samples were analyzed by flow cytometry (MoFlo XDP, Beckman, CA, USA).

**Immunofluorescence staining**

Cells were plated into each well of 6-well plates. After 24 h, the cells were exposed to 2 Gy radiation. The cells were fixed with 4% paraformaldehyde (Sigma) for 15 min. The cells were incubated with primary antibody, i.e., mouse anti-phospho-Histone H2AX (Ser139) (provide source) and subsequent incubation with Dylight 488, Goat Anti-Rat IgG secondary antibody. The cells were counter-stained with DAPI. Images were acquired.

**Neutral comet assay**

Cells were cultured in 6-well plates. After 24 h, the cells were irradiated with 6 Gy and were collected for the experiment. The length of the appendix was calculated using the CASP software. Tail moment was used as the parameter of DNA damage using the following formula: Tail moment = fraction of DNA in the tail × tail length.

**FFA ELISA assay**

Total 5×10⁶ cells were collected and used for FFA assay. After centrifuge, the cell pellet was resuspended with 1×PBS to make the cell concentration reach to 1 million/ml. Then the cells were broken by ultrasound and the supernatant collected after centrifuge, and this was used for ELISA assay. FFA concentration was quantified with the human free fatty acid ELISA kits (Jianglai Bio, China) to detect cell FFA in cell lysates.

**FFA and TLR4 inhibitor treatment**

Cells were cultured in 6-well plates. The cells treated with FFA at 50 μM, and continue to be cultivated for 24 h, then the cells were treated with TLR4 inhibitor (TLR4-IN-C34) at a concentration of 10 μM, 50 μM and 100 μM in CNE-2/AKR1B10 cells. After 48 hours, the cells of each group including the control were collected and the protein was extracted for western blot analysis.

**Tumorigenesis assay in tumor xenograft model of nude mice**

5-week-old female BALB/C nude mice were purchased from the Hunan SJA Laboratory Animal Company (Changsha, China) and were maintained under specific pathogen-free conditions. 24 mice were used for the experiment and four groups were established randomly. Six mice in each group were subcutaneously injected with 2×10⁶ cells (CNE-2/Vector cells or CNE2/AKR1B10 cells) into the right flank. Tumor volume was monitored every two days and when the tumor volumes reached 100-200 mm³, the tumors were exposed to 6 Gy IR. Two weeks after IR, tumor volume was measured and calculated. The
study protocol complied with the ARRIVE guidelines and was carried out by following the National Institutes of Health guide for the care and use of Laboratory animals.

**Western blotting**

Total protein was extracted by using RIPA buffer, quantified by BCA assay, and subjected to SDS-PAGE gel electrophoresis and transferred to nitrocellulose membrane (NC). The blot was blocked with 5% BSA or 5% non-fat milk, and then incubated respectively with anti-AKR1B10 antibody (prepared by our laboratory), p-chk1/2 (Catalog #AC506, AC508, Beyotime), chk1/2 (Catalog # 2662, 2260, CST), cleaved-PARP (Catalog #5625, CST), PARP (Catalog #9524, CST), cleaved-caspase3 (Catalog #9664, CST), caspase3, p-NFkB (Thr183/Tyr185) (Catalog #4671, CST), NF-KB (D14E12) (Catalog #8242,CST), p-IkBα (Ser473) (Catalog #4060, CST), IKBα, TLR4 (Catalog #35463,SAB), MyD88 (Catalog #41191, SAB), β-actin (Catalog #60008-1, Proteintech) overnight at 4 °C. Then the blot was incubated with the Goat anti -rabbit secondary antibody Catalog #ZB-2301, ZSGB-BIO) or Goat anti -Mouse secondary antibody (Catalog #ZB-2305, ZSGB-BIO) for 1.5 hours on a room temperature. After extensive washing in PBST, the expression levels of the proteins were detected by Quantity-one software (Bio-Rad Laboratories, USA) using the ECL-chemiluminescent kit. The signal of protein bands was quantified by ImageJ software for Windows (NIH, USA).

**Statistical analysis**

All the cell experiments were repeated three times. The differences between the control group and the experimental groups were determined by Student’s t test. Data was analyzed using SPSS 19 statistical software (SPSS, Inc, Chicago, IL, U.S.A.), and the results were considered significant when the p value <0.05.

**Results**

**AKR1B10 is associated with the radio-resistance of NPC**

58 NPC patients accepting radiotherapy were recruited in this study. According to the literature evaluation criteria, they were divided into 28 radioresistance patients and 30 radiosensitive patients. AKR1B10 expression levels were detected in the NPC tissues obtained before any anti-cancer therapy. Immunohistochemical score analysis of AKR1B10 expression revealed a range of expression levels in NPC (representative images shown in Fig. 1a), and higher expression of AKR1B10 detected in radiation resistant patients (Fig. 1b). Clinical and histopathological data of the NPC patients are presented in Table 1. AKR1B10 expression levels in the radioresistant group was significantly higher and stronger than that in radiosensitive group (P=0.002). There were no significant differences in age (P=0.662), gender ratio (P=0.442), N classification (P=0.535), M classification (P=0.269) and clinical stage (P=0.126).

**Table 1. The relationship between AKR1B10 expression and the clinical characteristics of the NPC patients**

| Characteristics | AKR1B10 expression levels | Fisher's exact tests | Correlation analysis |
|----------------|---------------------------|----------------------|---------------------|
|                | 0 | 1 | 2 | 3 | Values | p Values | Values | p Values |
| Cancerous tissues | 9 | 31 | 14 | 4 | 58 | 1.717 | 0.662 | 0.106 | 0.421 |
| Age <45         | 2 | 6 | 5 | 1 | 14 | 2.738 | 0.442 | 0.190 | 0.157 |
|               | 7 | 25 | 9 | 3 | 44 | 12.384 | 0.004 | 0.050 | 0.715 |
| Gender Male     | 6 | 18 | 5 | 2 | 31 | 3.602 | 0.269 | 0.196 | 0.133 |
| Female          | 3 | 13 | 9 | 2 | 27 | 3.082 | 0.364 | 0.188 | 0.157 |
| T classification | 7 | 7 | 8 | 3 | 25 | 4.381 | 0.128 | 0.281 | 0.047 |
| T1-2            | 2 | 4 | 6 | 1 | 33 | 4.381 | 0.128 | 0.281 | 0.047 |
| T3-4            | 2 | 4 | 6 | 2 | 33 | 8.623 | 0.029 | 0.160 | 0.225 |
| N classification | 7 | 8 | 6 | 2 | 18 | 9.259 | 0.020 | 0.160 | 0.225 |
| N0-N1           | 2 | 8 | 6 | 2 | 18 | 7.259 | 0.020 | 0.160 | 0.225 |
| N2-3            | 7 | 23 | 8 | 2 | 40 | 13.047 | 0.002 | 0.456 | 0.000 |
| M classification | 8 | 27 | 11 | 2 | 48 | 13.047 | 0.002 | 0.456 | 0.000 |
| M0              | 1 | 4 | 3 | 2 | 10 | 13.047 | 0.002 | 0.456 | 0.000 |
| Clinical stage  | 0 | 1 | 2 | 1 | 4 | 13.047 | 0.002 | 0.456 | 0.000 |
| I-II            | 9 | 30 | 12 | 3 | 54 | 13.047 | 0.002 | 0.456 | 0.000 |
| Pathological type | 2 | 24 | 8 | 3 | 37 | 13.047 | 0.002 | 0.456 | 0.000 |
| Differentiated  | 2 | 4 | 8 | 3 | 37 | 13.047 | 0.002 | 0.456 | 0.000 |
| Undifferentiated | 1 | 3 | 8 | 1 | 21 | 13.047 | 0.002 | 0.456 | 0.000 |
| Radiotherapy evaluation | 0 | 15 | 9 | 4 | 28 | 13.047 | 0.002 | 0.456 | 0.000 |
| Radiosensitive  | 9 | 18 | 5 | 0 | 30 | 13.047 | 0.002 | 0.456 | 0.000 |

*p <0.05, **p<0.01, ***p<0.001
Figure 1. The expression of AKR1B10 in patients of radiotherapy resistance and radiotherapy sensitivity. (A) AKR1B10 expression detected by immunochemistry, and images a-d are representative images of 4 levels of expression from 0 to 3 score, such as 0 for no staining (a), 1 for week staining (b), 2 for moderate staining (c), 3 for strong staining (d). (B) Immunohistochemical detection of AKR1B10 expression in radio-sensitive and radio-resistant patients.

AKR1B10 enhances the radioresistance of NPC cells

CNE-2 cells with stable overexpression of AKR1B10 were constructed. AKR1B10 protein and mRNA levels were detected in the CNE-2/AKR1B10 by western blot and real-time fluorescent quantitative PCR (RT-PCR) (Fig. 2a and b). We performed colony formation assays and calculated the survival rate of the cells. As showed in Fig. 2c and 2d, AKR1B10 overexpression significantly increased the survival rate of CNE-2 cells treated with 4 or 6 Gy radiation. We checked the change in cell apoptosis by flow cytometry using Annexin V-APC/7-AAD staining. AKR1B10 overexpression significantly decreased the rate of apoptosis in CNE-2 cells treated with 6 Gy radiation (Fig. 2e and f). We also detected the activation of caspase-3 and poly (ADP-ribose) polymerase (PARP) (Fig. 2g and 2h), which are the markers of cell apoptosis. Cleaved PARP and cleaved caspase-3 significantly decreased in AKR1B10 overexpression cells after IR treatment for 48h. These results suggest that AKR1B10 overexpression enhances cell radiotherapy resistance, increases cell survival, and reduces cell apoptosis.

AKR1B10 reduces DNA damage and cell cycle arrest in NPC cells

To evaluate IR-induced DNA damage during radiotherapy, we evaluated the level of γH2AX as an indicator of double-strand breaks (DSB) after IR by immunofluorescence assay. AKR1B10 overexpression significantly decreased the number of γ-H2AX foci in the CNE-2 cell lines at both 12 h and 24 h after 2 Gy radiation (Fig. 3a and b). We also calculated the number of the cells with more than 20 γH2AX foci (Fig. 3c), and arrived at the similar conclusion that AKR1B10 overexpression alleviated DNA damage. At the same time, we performed single-cell gel electrophoresis (neutral comet assay) and measured tail moment (tail moment = fraction of DNA in the tail×tail length), which positively correlated with the level of DNA damage in a cell [25]. Tail moment was shorter in CNE-2/AKR1B10 than CNE-2/Vector, suggesting that AKR1B10 overexpression inhibits DNA damage undergoing repair (Fig. 3d and e).

CHK1 and CHK2, two important effectors of cell cycle progression, are phosphorylated when DNA damage happens, which leads to cell arrest, thus giving the cell time to repair DNA [11]. We found that AKR1B10 overexpression induced the expression levels of CHK1 (Fig. 3f & 3g). The phosphorylation level of CHK1 was higher in CNE-2/AKR1B10 at 4h after IR treatment than CNE-2/Vector. However, at 24 h after IR, the phosphorylation level of CHK1 was significantly lower in CNE-2/AKR1B10 than CNE-2/Vector, suggesting that AKR1B10 may induce the cells to repair DNA damage. However the AKR1B10 expression did not affect the expression of CHK2 or its phosphorylation induced by IR (Fig. 3f & 3h).

AKR1B10 promotes NPC radioresistance through activation of the NF-κB pathway

Activation of the NF-κB signaling pathway plays an important role in the radioresistance of tumor cells [26]. Inactivated NF-κB always binds to IκB to become homodimer, and when NF-κB is activated by phosphorylation, IκB will be phosphorylated to be degraded [27]. We found that IR induced the expression of phosphorylated NF-κB and IκBα at 4h after IR treatment than CNE-2/Vector. However, at 24 h after IR, the phosphorylation level of IκBα was significantly lower in CNE-2/AKR1B10 than CNE-2/Vector, suggesting that AKR1B10 may induce the cells to repair DNA damage. However the AKR1B10 expression did not affect the expression of IκB or its phosphorylation induced by IR (Fig. 3f & 3h).
IKBα at 4 h and 12 h after IR (Fig. 4a, b and c). Furthermore, we used a lentivirus system to construct an AKR1B10 knockdown cell line (Fig. 4d). AKR1B10 silencing also inhibited the phosphorylation of NF-κB 8 h after IR (Fig. 4e and f). These studies show that AKR1B10 can increase NF-κB activity, which suggested that AKR1B10 contributed to NPC radioresistance by activating the IKBα/NF-κB signaling pathway.

Figure 2. AKR1B10 forcing expression promoted proliferation and reduced apoptosis of NPC cells. (A and B) AKR1B10 expression confirmed at CNE-2 cells by Western blot and qRT-PCR. (C and D) The proliferation of CNE-2/AKR1B10 cells verified by clone formation assay. The experiments repeated three times. (E and F) The effect of AKR1B10 expression on CNE-2 cell apoptosis detected by Annexin V-APC, 7-AAD, and Flow cytometry after IR treatment. (G) Expression levels of cleaved-caspase-3, cleaved-PARP in CNE-2/AKR1B10 cells after IR (6 Gy) 48 hours determined by Western blot. (H) Quantification and statistics for the cleaved PARP and cleaved Caspase 3 expression. IR: irradiation; Gy: Gray; AKR1B10: V: vector, psin-EF2-puromycine; CNE-2/A: CNE-2/AKR1B10, AKR1B10 expressed CNE-2 cells; CNE-2/V: CNE-2/AKR1B10 vector, CNE-2 control cells; *p<0.05.
Figure 3. Evaluation of DNA damage after irradiation in AKR1B10-overexpression NPC cells. (A) The γH2AX staining of CNE-2/AKR1B10 cells (the scale bar represents 50 µm). (B and C) Statistics of the percentage of γH2AX foci and foci greater than 20 in CNE-2/AKR1B10 and CNE-2/vector cells. (D and E) The comet assay of CNE-2/AKR1B10 cells after IR treatment. D is one of the representative Images and E is the statistics result of three experiments (counting 100 cells per group, Scale bar 200µm). (F) The effect of AKR1B10 expression on cell cycle checkpoint proteins expression by Western blot after IR treatment. (G and H) The relative quantification analysis of the change of phosphorylated CHK1 and CHK2 between the control group and the experimental groups. The signal s of protein bands relative to β-actin in three experiments were quantified by ImageJ software. IR: irradiation; Gy: Gray; A: AKR1B10; V: vector, psin-EF2-puromycine; CNE-2/A: CNE-2/AKR1B10, AKR1B10-expressed CNE-2 cells; CNE-2/V: CNE-2/AKR1B10 vector, CNE-2 control cells; p-CHK1: phosphorylated CHK1; p-CHK2: phosphorylated CHK2. *P < 0.05; **P < 0.01.

AKR1B10 activates TLR4/NF-κB signaling pathway by increasing FFA in NPC

AKR1B10 promotes FFA synthesis by stabiling ACCα [15]. To elucidate the precise mechanisms by which AKR1B10 induces radioresistance of NPC cells, we detected the FFA content in the NPC cells. The FFA level was significantly increased in CNE-2/AKR1B10 (Fig. 5A), and significantly decreased in CNE-2/AKR1B10 with AKR1B10 shRNA transfection
Then we used 0, 50, 100 and 200 μM FFA to treat CNE-2/AKR1B10 to detect whether the NF-κB signaling was activated. The results showed that the level of phosphorylated NF-κB (p-NF-κB) was increased with the FFA concentration increasing. The expression level of TLR4 and phosphorylated IKBα (p-IKBα) also increased in FFA treated cells (Fig. 5C). This result was further confirmed in the CNE-2/vector and CN-2/AKR1B10 cells after treated with 100 μM FFA (Fig. 5D). Moreover, exogenous FFA significantly induced nuclear translocation of NF-κB p65 (Fig. 5E). Furthermore, an inhibitor of TLR4 signaling, TLR4-IN-C34, which is an aminomono-saccharide that inhibits TLR4 signaling by docking with the hydrophobic pocket of the TLR4 co-receptor, myeloid differentiation protein-2 (MD-2), could block FFA-induced NF-κB activation in CNE-2/AKR1B10 (Fig. 5F). These results illustrated that AKR1B10 could activate TLR4/NF-κB signaling pathway via promoting the FFA synthesis in NPC.

**AKR1B10 promotes radioresistance of NPC in vivo**

To evaluate the radioresistance induced by AKR1B10 in an *in vivo* animal model, we established a NPC xenograft mice model by subcutaneously implanted NPC cells (2×10⁶ cells) into balb/c nude mice. When tumor volume reached approximately 100-200 mm³, the mice were subjected to IR. However, tumor volume in the experimental group was larger than that in the control group after exposure to 6 Gy IR (Fig. 6A). IR decreased the rate of tumor growth in both the normal control and experimental groups (Fig. 6B). The rate of tumor growth was higher in the CNE-2/AKR1B10 group than that in the CNE-2/Vector group (Fig. 6C). Immunohistologic evaluation of tumor tissues showed that the γH2AX expression level was lower in the CNE-2/AKR1B10 group than that in CNE-2/Vector group (Fig. 6D), suggesting that AKR1B10 promoted radioresistance of NPC.

Together our data demonstrates that AKR1B10 facilitates radioresistance of NPC via promoting the FFA synthesis and activating TLR4/NF-κB signaling pathway (Fig. 7).

**Discussion**

Radiotherapy is the primary mode of treatment used for NPC and the 5-year survival rate of NPC patients in stage I-IVB is about 85% [28]. The main obstacles in the treatment of NPC is the intrinsic and therapy-induced radioresistant behavior of tumor cells. IR can lead to DNA single or double-stranded breaks. Previous research has demonstrated that AKR1B10, which regulates the balance of retinoic acid...
and lipid metabolism [27], formation of adducts of carbonyl compounds with DNA, blocks DNA replication and RNA transcription, leading to DNA breaks and damage. Thus AKR1B10 promotes cell survival through cytotoxic carbonyl detoxification. In our study, the analysis of resected specimens from NPC radioresistant patients showed that the expression of AKR1B10 is significantly higher compared with radiosensitive patients. Moreover, we also demonstrated that NF-κB activation might be induced by IR in vitro and in vivo, and NPC cells with constitutive AKR1B10 expression are associated with severe DNA damage outcome after IR. Therefore, we considered that AKR1B10 is involved in therapeutic resistance to radiotherapy in NPC.

AKR1B10 has been shown to be a feasible biomarker for radioresistance, infrared IR-induced cell apoptosis and senescence. To study how AKR1B10 affects apoptosis during radiotherapy, we studied the activation of some apoptosis related proteins. The caspase family are important parts in the apoptotic pathway. Caspase-3 is a key executor of apoptosis, which is responsible for the cleavage of many key proteins, such as ribozyme poly (ADP-ribose) polymerase (PARP) [29]. Our study suggests that enhanced AKR1B10 level after radiotherapy can inhibit the apoptosis cascade. The main mechanisms by which radiotherapy works are by inducing DNA strand breaks and cell apoptosis.

The repair pathways in place to combat DNA damage include non-homologous end terminal attachment repair and homologous recombination (HR) repair. CHK1 is a responder protein kinase, which can regulate S-phase progression and G2/M cell cycle arrest. When increased, CHK1 upregulation gives more time to repair damaged DNA. Our results shows that AKR1B10 overexpression in NPC cells resulted in increased Chk1 activation phosphorylation after 4 h of IR, stronger DNA repair ability, decreased tumor cell apoptosis, and enhanced radioresistance. However, after 24 h of IR, we found a decrease in chk1 expression, indicating that DNA damage has been repaired. Therefore, AKR1B10 may play a major role in the IR resistance by enhancing DNA repair ability of radioresistant tumor cells.

![Figure 5. Enhanced AKR1B10 expression activates the TLR4/ NF-κB signaling pathway.](image)

(A and B) The effect of AKR1B10 expression on FFA content. AKR1B10 expression increases FFA content of CNE-2/AKR1B10 cells (CNE-2/A), meanwhile, knockdown of AKR1B10 expression decreases FFA content. (C) 0, 50, 100 and 200 µM FFA were used to treat CNE-2/AKR1B10 cells and the expression levels of TLR4, p-IKBa and p-NF-κB p65 as well as AKR1B10 were detected by western blot. (D) The expression levels of TLR4, p-IKBa and p-NF-κB p65 as well as AKR1B10 were further confirmed in the CNE-2/vector and CNE-2/AKR1B10 cells after treated with 100 µM FFA. (E) The effect of FFA on NF-κB p65 entry into the nucleus. (F) The effect of FFA inhibitors on TLR4 signaling pathway. A: AKR1B10, V: vector, psi-n-EGF-puromycin, CNE-2/A: CNE-2/AKR1B10, AKR1B10 expressed CNE-2 cells; CNE-2/V: CNE-2/AKR1B10 vector, CNE-2 control cells; FFA: Free fatty acid; H3: H3 histone; TLR4-IN-C34: TLR4 inhibitor; p-IKBa: phosphorylated IKBa; p-NF-κB: phosphorylated NF-κB. *P < 0.05.
Figure 6. AKR1B10 promotes NPC radioresistance in vivo. (A) Whole tumors excised from mice injected with CNE-2/Vector, CNE2/Vector+IR, CNE2/AKR1B10, CNE2/AKR1B10+IR. (B and C) Tumor volumes and weight were determined. (D) Analysis of tumor tissue by HE staining and immunohistochemical staining. IR: irradiation; CNE-2/A: CNE-2/AKR1B10, AKR1B10-expressed CNE-2 cells; CNE-2/V: CNE-2/AKR1B10 vector, CNE-2 control cells; *P < 0.05; **P < 0.01.

Figure 7. Proposed Schematic for AKR1B10 activating TLR4/NF-κB signaling pathway by promoting FFA synthesis in NPC. AKR1B10-induced FFA synthesis activates the TLR4/ NF-κB signaling axis, IKBα phosphorylation and NF-κB nuclear translocation, which then regulates cell cycle arrest and DNA damage repair. IR: irradiation; FFA: Free fatty acid; →, activation or upregulation; ┴ inhibition or downregulation.
NF-κB family of transcription factors plays an important role in inflammation and immune response [30, 31]. When activated, phosphorylation of the IκB protein and its rapid degradation through the ubiquitin-proteasome pathway, releases NF-κB into the nucleus and regulates gene expression [32-34]. Upon TLR activation, MYD88 recruits IRAK1 (interleukin 1 receptor associated kinase 1) and IRAK4 (interleukin 1 receptor associated kinase 4), forming the NF-κB activation complex and inducing genes encoding inflammatory cytokines expression [35]. FFA stimulates the TLR4/NF-κB signaling pathway in adipose and macrophages and is involved in inflammation and tumor progression [36]. Treatment with FFA markedly induced the phosphorylation of NF-κB and TLR4 in CNE-2 cells, and knockdown of AKR1B10 in NPC cells resulted in the decrease of NF-κB phosphorylation and TLR4 levels.

In this study, we reported the effect of AKR1B10 on radioresistance of NPCs, and explored the molecular mechanism by which AKR1B10 contributes to this radioresistance. Taken together, we identified a mechanism underlying the association between NF-κB and radioresistance (Fig. 7). AKR1B10-induced FFA synthesis activates the TLR4/NF-κB signaling axis, IκBα phosphorylation and NFκB nuclear translocation which then regulates cell cycle arrest and DNA damage repair. Understanding the mechanism behind radioresistance of NPCs can lead to improved therapeutic approaches, possibly by combination of chemotherapy and radiation.

Acknowledgements

This work was supported by the Hunan Province Science Fund for Distinguished Young Scholars (No.2018JJ1021); the Key R&D Program of Hunan Province (2017SK2172); the Natural Science Foundation of Hunan Province (No.2017JJ2003, 2017JJ2004, 2019JJ50022); the Hunan Province Technological Innovation Guiding Plan, Clinical Medical Technology Innovation Guidance Project (2017SK51101); the Health Department project of the Hunan Province (No.B2017182, B20180378, B20180266, B2019001, C2019003); the Education Department project of Hunan Province (No.18C0066); and the Science and Technique Foundation of Chenzhou (jsty2017021, jsty2017023, zdyf201837, zdyf201840).

Ethics approval and consent to participate

This study was approved by the ethics committee of the First People's Hospital of Chenzhou City.

Authors’ contributions

DXL conceived and designed the experiments. XTL, JYQ and JL developed the methods. XTL, KG, WHL and JJ conducted the animal experiment, and recruited and managed NPC patients. ZH, RZH, LLD, WHL and CLX participated in data analysis and interpretation. ZH, XTL, CLX and DXL were involved in writing, review and revision of the manuscript. All authors read and approved the final manuscript.

Competing Interests

The authors have declared that no competing interest exists.

References

1. Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet. 2005;365:2041-54. https://doi.org/10.1016/S0140-6736(05)66698-6.
2. Al-Fjej F, Kumar R, Wiegmanns A, Lakhani SR, Brown MP, Khanna HK. Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes. Oncogene. 2010;29:6685-98. https://doi.org/10.1038/ onc.2010.407.
3. Manic G, Obrist F, Sintigu A, et al. Trial Watch: Targeting ATM-CHK2 and ATR-CHK1 pathways for anticancer therapy. Mol Cell Oncol. 2015; 2: e0112976.
4. Rogakou EP, Pilch DR, Orr AH, et al. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273: 5858-68.
5. Reinhardt HC, Yaffe MB. Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and Mkk2. Curr Opin Cell Biol. 2009; 21: 245-55.
6. Yan R, Zu X, Ma J, et al. Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer treatment. Int J Cancer. 2013; 132: 301-6.
7. Cross B, Hyndman DJ, Gallego O, et al. Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: consequences for retinoid metabolism. Biochem J 2003; 373: 973-9.
8. Wang C, Yan R, Luo D, et al. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls. J Biol Chem. 2009; 284: 26742-8.
9. Tilbohrs S, Corthouts J, Verhoeyen E, et al. The role of Nuclear Factor-kappa B signaling in human cervical cancer. Crit Rev Oncol Hematol. 2017; 120: 141-50.
10. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008; 132: 344-62.
11. Perkins ND. Emerging from NF-kappaB's shadow, SUMOylated IkappaBalpha represses transcription. Cancer Cell. 2013; 24: 139-40.
12. Zeng Z, Umemura A, Sanchez-Lopez E, et al. NF-kappaB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. Cell. 2016; 164: 896-910.
13. Li Y, Xie G, Li L, et al. [The effect of TLR4/MyD88/NF-kappaB signaling pathway on proliferation and apoptosis in human nasopharyngeal carcinoma 5-8F cells induced by LPS]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015; 29: 1012-5.
14. Patra AB, Nishi K, Shiraishi R, et al. Jellyfish collagen stimulates production of TNF-alpha and IL-6 by J774.1 cells through activation of NF-kappaB and JNK via TLR4 signaling pathway. Mol Immunol. 2014; 58: 32-7.
15. Ma J, Yan R, Zu X, et al. Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-alpha in breast cancer cells. J Biol Chem. 2008; 283: 3418-23.
16. Suganami T, Tanimoto-Koyama K, Nishida J, et al. The Role of the Toll-like receptor 4/NF-kappaB pathway in saturated fatty acid-induced inflammatory changes in the interaction between adipocytes and macrophages. Arterioscler Thromb Vasc Biol. 2007; 27: 84-91.
17. Li LN, Xiao T, Yi HM, Zheng Z, Qu JQ, Huang W, et al. MiR-125b Increases NF-kappaB Restricts Inflammation and Tumor Progression in Nasopharyngeal Carcinoma. Mol Cancer Ther 2017;16:2094-106.
18. Yuan L, Yi HM, Yi H, Qu JQ, Zhu JF, Li LN, et al. MiR-203 and MiR-204 sensitizes nasopharyngeal carcinoma to irradiation by targeting IL8/AKT Signaling Pathway. Mol Cancer Ther 2016;15:2984-106.
19. Ylan L, Yi HM, Yi H, Qu JQ, Zhu JF, Li LN, et al. Reduced RIPK3 enhances nasopharyngeal carcinoma radioresistance by increasing ERK and AKT activity. Oncotarget 2016;7:11463-77.
22. Guo Y, Luo W, Hu Z, et al. Low expression of Aldo-keto reductase 1B10 is a novel independent prognostic indicator for nasopharyngeal carcinoma. Cell Biosci. 2016; 6: 18.
23. Li J, Guo Y, Duan L, et al. AKR1B10 promotes breast cancer cell migration and invasion via activation of ERK signaling. Oncotarget. 2017; 8: 33694-703.
24. Li Y, Li X, Qu J, Luo D, Hu Z. Cas9 mediated correction of β-catenin mutation and restoring the expression of protein phosphorylation in colon cancer HCT-116 cells decrease cell proliferation in vitro and hamper tumor growth in mice in vivo. Onco Targets Ther. 2020;13:17-29.
25. Olive PL, Banáth JP, Durand RE. Heterogeneity in radiation-induced DNA damage and repair in tumor and normal cells measured using the "comet" assay. 1990. Radiat Res. 2012; 178: AV35-42.
26. Andersson-Anvret M, Forsby N, Klein G, et al. Relationship between the Epstein-Barr virus and undifferentiated nasopharyngeal carcinoma: correlated nucleic acid hybridization and histopathological examination. Int J Cancer. 1977; 20: 486-94.
27. van Weverwijk A, Koundouros N, Iravani M, et al. Metabolic adaptability in metastatic breast cancer by AKR1B10-dependent balancing of glycolysis and fatty acid oxidation. Nat Commun. 2019; 10: 2698.
28. Zhang G, Zhang K, Li C, et al. Serum proteomics identify potential biomarkers for nasopharyngeal carcinoma sensitivity to radiotherapy. Biosci Rep. 2019; 39.
29. Fernandes-Alnemri T, Litwack G, Alnemri ES. CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme. J Biol Chem. 1994; 269: 30761-4.
30. Baeuerle PA, Henkel T. Function and activation of NF-kappa B in the immune system. Annu Rev Immunol. 1994; 12: 141-79.
31. Baeuerle PA, Baltimore D. NF-kappa B: ten years after. Cell. 1996; 87: 13-20.
32. Traenckner EB, Pahl HL, Henkel T, et al. Phosphorylation of human I kappa B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF-kappa B activation in response to diverse stimuli. EMBO J. 1995; 14: 2876-83.
33. Scherer DC, Brockman JA, Chen Z, et al. Signal-induced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A. 1995; 92: 11259-63.
34. Chen ZJ, Parent L, Maniatis T. Site-specific phosphorylation of IkappaBalpha by a novel ubiquitination-dependent protein kinase activity. Cell. 1996; 84: 853-62.
35. Min Y, Kim MJ, Lee S, et al. Inhibition of TRAF6 ubiquitin-ligase activity by PRDX1 leads to inhibition of NFKB activation and autophagy activation. Autophagy. 2018; 14: 1347-58.
36. Jiang Y, Zhou J, Luo P, et al. Prosaposin promotes the proliferation and tumorigenesis of glioma through toll-like receptor 4 (TLR4)-mediated NF-κB signaling pathway. EBioMedicine. 2018; 37: 78-90.